Hutchison China Meditech Ltd - China-based biopharmaceutical company - Says surufatinib granted approval for drug registration by the National Medical Products Administration of China to treat non-pancreatic neuroendocrine tumours. Drug will be marketed as Sulanda. "We are very pleased to have achieved this major milestone for Chi-Med. The approval of surufatinib, our first un-partnered oncology drug, is a strong testament to our in-house research and development capability," Chief Executive Officer Christian Hogg says.
Current stock price: 433.00 pence
Year-to-date change: up 12%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Hutchmed (HCM)